Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Pharmacol Sin ; 43(12): 3045-3054, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36050519

ABSTRACT

Immunotherapy that activates immune systems for combating cancer has yielded considerable clinical benefits recently. However, the immunosuppressive tumor microenvironment (ITME) is a major hurdle to immunotherapy as it supports tumor to evade immune surveillance. Reversing ITME facilitates the recruitment and activation of antitumor immune cells, thereby promoting immunotherapy. Our group has developed various nanosized drug delivery systems (NDDSs) to modulate ITME with enhanced efficacy and safety. In the review we introduce the ITME-remodeling strategies for improving immunotherapy based on NDDSs including triggering tumor cells to undergo immunogenetic cell death (ICD), applying tumor vaccine, and directly regulating intratumoral immune components (immune cells or cytokines). In order to guide the design of NDDSs for amplified effects of antitumor immunotherapy, the contributions and future directions of this field are also discussed.


Subject(s)
Cancer Vaccines , Neoplasms , Humans , Immunotherapy , Drug Delivery Systems , Tumor Microenvironment , Neoplasms/therapy , Cancer Vaccines/therapeutic use , Immunologic Factors/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...